Stock Market News3 months Prime Medicine (NYSE:PRME) Receives Buy Rating from HC Wainwright MarketBeat
HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a report on Friday.
XHC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a report on Friday.
X